KDR and breast cancer: For VEGFR2/KDR rs11133360 C/T, TT carriers had improved OS (HR = 0.63, 95% CI: 0.40–0.99, p-val = 0.045) in APD, partially in line with our earlier study that any T at this locus was associated with improved PFS in mCRC, renal cell carcinoma and breast cancer patients treated with BVZ (6,7,22 and references therein).